Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863304 · ClinicalTrials.gov registry record · Phase 3
Tanezumab in Osteoarthritis of the Hip or Knee (2)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 849
- Enrollment target
NCT00863304: Completed Phase 3 study, sponsored by Pfizer.
NCT00863304 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 849 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00863304, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 849 participants
- Enrollment target
Study Summary
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
Primary Outcome
WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating sc
Interventions
- OTHER placebo
- DRUG naproxen
- BIOLOGICAL tanezumab 10 mg
- BIOLOGICAL tanezumab 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2009-06-09 |
| Est. Completion | 2010-08-16 |
| Phase | Phase 3 |
What the finished NCT00863304 record still lists
NCT00863304 is an interventional study that assigns participants to a tested intervention. The registered 849 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00863304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00863304 about?
NCT00863304 is a clinical study titled "Tanezumab in Osteoarthritis of the Hip or Knee (2)". Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
What is the current status of trial NCT00863304?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 849 participants. The study started on 2009-06-09. Estimated completion is 2010-08-16.
What interventions are being tested in trial NCT00863304?
The interventions under investigation include: placebo (OTHER), naproxen (DRUG), tanezumab 10 mg (BIOLOGICAL), tanezumab 5 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00863304?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00863304's enrollment target sits among peer trials
849 389th of 2000 higher than 1,612 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI